Skip to main content

Influenza virus vaccine, inactivated Disease Interactions

There are 4 disease interactions with influenza virus vaccine, inactivated.

Major

Influenza vaccine (applies to influenza virus vaccine, inactivated) GBS

Major Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome

The use of influenza vaccine has been associated with an elevated risk of Guillain-Barré syndrome (GBS). It is not recommended to administer this vaccine if GBS has occurred within 6 weeks following previous influenza vaccination. Care and close monitoring is recommended and consideration of the potential benefits and risks should be assessed.

Switch to professional interaction data

Major

Influenza vaccine (applies to influenza virus vaccine, inactivated) neurologic disorders

Major Potential Hazard, High plausibility.

Influenza vaccine should be withheld, pending stabilization, in patients with active neurologic disorders associated with changing neurological status. Neurologic signs or symptoms following administration of an influenza vaccine is a contraindication to future use.

Switch to professional interaction data

Major

Vaccination (applies to influenza virus vaccine, inactivated) infections

Major Potential Hazard, High plausibility. Applicable conditions: Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

Switch to professional interaction data

Moderate

Vaccines (inactivated)/toxoids (applies to influenza virus vaccine, inactivated) immunodeficiency

Moderate Potential Hazard, High plausibility.

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

Switch to professional interaction data

Influenza virus vaccine, inactivated drug interactions

There are 295 drug interactions with influenza virus vaccine, inactivated.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.